Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma [0.03%]
针对多发性骨髓瘤靶向B细胞成熟抗原的免疫毒素的临床前开发
Zoe Shancer,Matthew Williams,Austin Igelman et al.
Zoe Shancer et al.
Background: Multiple myeloma (MM) is a B-cell malignancy that is incurable for the majority of patients. New treatments are urgently needed. Recombinant immunotoxins (RITs) are chimeric proteins that are composed of the F...
Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers [0.03%]
曲妥珠单抗引起的心脏毒性：目前的认识、挑战与前景
Nishant Mohan,Jiangsong Jiang,Milos Dokmanovic et al.
Nishant Mohan et al.
Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associate...
Mitchell Ho
Mitchell Ho
Single domain antibodies have emerged as a new class of therapeutic molecules in antibody engineering. A single domain antibody (shark VNAR), in contrast to a conventional antibody (Fv), is capable of binding a buried functional site consis...